Cargando…

Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling

BACKGROUND: Major depressive disorder (MDD) is a severe mental disorder related to the deficiency of monoamine neurotransmitters, particularly to abnormalities of 5-HT (5-hydroxytryptamine, serotonin) and its receptors. Our previous study suggested that acute treatment with a novel curcumin derivati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianxin, Chen, Ling, Li, Gaowen, Chen, Xiaojuan, Hu, Sisi, Zheng, Liang, Luria, Victor, Lv, Jinpeng, Sun, Yindi, Xu, Ying, Yu, Yingcong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360862/
https://www.ncbi.nlm.nih.gov/pubmed/32733195
http://dx.doi.org/10.3389/fnins.2020.00701
_version_ 1783559298059599872
author Li, Jianxin
Chen, Ling
Li, Gaowen
Chen, Xiaojuan
Hu, Sisi
Zheng, Liang
Luria, Victor
Lv, Jinpeng
Sun, Yindi
Xu, Ying
Yu, Yingcong
author_facet Li, Jianxin
Chen, Ling
Li, Gaowen
Chen, Xiaojuan
Hu, Sisi
Zheng, Liang
Luria, Victor
Lv, Jinpeng
Sun, Yindi
Xu, Ying
Yu, Yingcong
author_sort Li, Jianxin
collection PubMed
description BACKGROUND: Major depressive disorder (MDD) is a severe mental disorder related to the deficiency of monoamine neurotransmitters, particularly to abnormalities of 5-HT (5-hydroxytryptamine, serotonin) and its receptors. Our previous study suggested that acute treatment with a novel curcumin derivative J147 exhibited antidepressant-like effects by increasing brain derived neurotrophic factor (BDNF) level in the hippocampus of mice. The present study expanded upon our previous findings and investigated the antidepressant-like effects of sub-acute treatment of J147 for 3 days in male ICR mice and its possible relevancy to 5-HT(1A) and 5-HT(1B) receptors and downstream cAMP-BDNF signaling. METHODS: J147 at doses of 1, 3, and 9 mg/kg (via gavage) was administered for 3 days, and the anti-immobility time in the forced swimming and tail suspension tests (FST and TST) was recorded. The radioligand binding assay was used to determine the affinity of J147 to 5-HT(1A) and 5-HT(1B) receptor. Moreover, 5-HT(1A) or 5-HT(1B) agonist or its antagonist was used to determine which 5-HT receptor subtype is involved in the antidepressant-like effects of J147. The downstream signaling molecules such as cAMP, PKA, pCREB, and BDNF were also measured to determine the mechanism of action. RESULTS: The results demonstrated that sub-acute treatment of J147 remarkably decreased the immobility time in both the FST and TST in a dose-dependent manner. J147 displayed high affinity in vitro to 5-HT(1A) receptor prepared from mice cortical tissue and was less potent at 5-HT(1B) receptor. These effects of J147 were blocked by pretreatment with a 5-HT(1A) antagonist NAD-299 and enhanced by a 5-HT(1A) agonist 8-OH-DPAT. However, 5-HT(1B) receptor antagonist NAS-181 did not appreciably alter the effects of J147 on depression-like behaviors. Moreover, pretreatment with NAD-299 blocked J147-induced increases in cAMP, PKA, pCREB, and BDNF expression in the hippocampus, while 8-OH-DPAT enhanced the effects of J147 on these proteins’ expression. CONCLUSION: The results suggest that J147 induces rapid antidepressant-like effects during a 3-day treatment period without inducing drug tolerance. These effects might be mediated by 5-HT(1A)-dependent cAMP/PKA/pCREB/BDNF signaling.
format Online
Article
Text
id pubmed-7360862
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73608622020-07-29 Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling Li, Jianxin Chen, Ling Li, Gaowen Chen, Xiaojuan Hu, Sisi Zheng, Liang Luria, Victor Lv, Jinpeng Sun, Yindi Xu, Ying Yu, Yingcong Front Neurosci Neuroscience BACKGROUND: Major depressive disorder (MDD) is a severe mental disorder related to the deficiency of monoamine neurotransmitters, particularly to abnormalities of 5-HT (5-hydroxytryptamine, serotonin) and its receptors. Our previous study suggested that acute treatment with a novel curcumin derivative J147 exhibited antidepressant-like effects by increasing brain derived neurotrophic factor (BDNF) level in the hippocampus of mice. The present study expanded upon our previous findings and investigated the antidepressant-like effects of sub-acute treatment of J147 for 3 days in male ICR mice and its possible relevancy to 5-HT(1A) and 5-HT(1B) receptors and downstream cAMP-BDNF signaling. METHODS: J147 at doses of 1, 3, and 9 mg/kg (via gavage) was administered for 3 days, and the anti-immobility time in the forced swimming and tail suspension tests (FST and TST) was recorded. The radioligand binding assay was used to determine the affinity of J147 to 5-HT(1A) and 5-HT(1B) receptor. Moreover, 5-HT(1A) or 5-HT(1B) agonist or its antagonist was used to determine which 5-HT receptor subtype is involved in the antidepressant-like effects of J147. The downstream signaling molecules such as cAMP, PKA, pCREB, and BDNF were also measured to determine the mechanism of action. RESULTS: The results demonstrated that sub-acute treatment of J147 remarkably decreased the immobility time in both the FST and TST in a dose-dependent manner. J147 displayed high affinity in vitro to 5-HT(1A) receptor prepared from mice cortical tissue and was less potent at 5-HT(1B) receptor. These effects of J147 were blocked by pretreatment with a 5-HT(1A) antagonist NAD-299 and enhanced by a 5-HT(1A) agonist 8-OH-DPAT. However, 5-HT(1B) receptor antagonist NAS-181 did not appreciably alter the effects of J147 on depression-like behaviors. Moreover, pretreatment with NAD-299 blocked J147-induced increases in cAMP, PKA, pCREB, and BDNF expression in the hippocampus, while 8-OH-DPAT enhanced the effects of J147 on these proteins’ expression. CONCLUSION: The results suggest that J147 induces rapid antidepressant-like effects during a 3-day treatment period without inducing drug tolerance. These effects might be mediated by 5-HT(1A)-dependent cAMP/PKA/pCREB/BDNF signaling. Frontiers Media S.A. 2020-07-08 /pmc/articles/PMC7360862/ /pubmed/32733195 http://dx.doi.org/10.3389/fnins.2020.00701 Text en Copyright © 2020 Li, Chen, Li, Chen, Hu, Zheng, Luria, Lv, Sun, Xu and Yu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Li, Jianxin
Chen, Ling
Li, Gaowen
Chen, Xiaojuan
Hu, Sisi
Zheng, Liang
Luria, Victor
Lv, Jinpeng
Sun, Yindi
Xu, Ying
Yu, Yingcong
Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling
title Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling
title_full Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling
title_fullStr Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling
title_full_unstemmed Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling
title_short Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT(1A)-Mediated cAMP Signaling
title_sort sub-acute treatment of curcumin derivative j147 ameliorates depression-like behavior through 5-ht(1a)-mediated camp signaling
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360862/
https://www.ncbi.nlm.nih.gov/pubmed/32733195
http://dx.doi.org/10.3389/fnins.2020.00701
work_keys_str_mv AT lijianxin subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT chenling subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT ligaowen subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT chenxiaojuan subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT husisi subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT zhengliang subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT luriavictor subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT lvjinpeng subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT sunyindi subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT xuying subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling
AT yuyingcong subacutetreatmentofcurcuminderivativej147amelioratesdepressionlikebehaviorthrough5ht1amediatedcampsignaling